At the beginning of August, preparations for Adaptimmune’s allogeneic MAGE-A4 program seemed to be near the finish line, with the company’s UK manufacturing facility almost done. The plan at the time ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

Adaptimmune was facing a financing cliff until Galapagos walked in with a sprawling licensing deal for a next-generation T-cell therapy that could total $665 million in biobucks. The multipronged deal ...

GSK gave Adaptimmune nearly $37 million as part of a rights deal. Adaptimmune said it expects to launch its first marketed therapy, possibly as soon as the end of this year. The company grew annual ...

Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The business ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. What Adaptimmune Does and Why Its Focus Is Changing ...

In the preceding three months, 4 analysts have released ratings for Adaptimmune Therapeutics (NASDAQ:ADAP), presenting a wide array of perspectives from bullish to bearish. The following table ...

About Adaptimmune Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing ...

Adaptimmune Therapeutics (ADAP) has received a new Buy rating, initiated by Mizuho Securities analyst, Mara Goldstein. Mara Goldstein issued a Buy rating for Adaptimmune Therapeutics’ stock based on ...

The Food and Drug Administration granted accelerated approval for Adaptimmune Therapeutics’ cell therapy Tecelra in treating a specific form of cancer. The drug is on track to treat patients with ...

Adaptimmune's stock has been moving in the wrong direction nearly all year long. Today, the biotech's shares are making an abrupt U-turn following a positive clinical update. What's fueling this ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min "I think it's impossible to ...